Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

advanced accelerator app-adr (AAAP) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced accelerator app-adr (AAAP) Related Businessweek News

No Related Businessweek News Found

advanced accelerator app-adr (AAAP) Details

Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine (MNM) diagnostic and therapeutic products in France, Italy, Spain, Israel, Canada, the United States, and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that is in Phase III clinical trials for the treatment of midgut gastroenteropancreatic neuroendocrine tumors (GEP-NETs); Somakit, a sterile and easy-to-use freeze-dried, or lyophilized reconstitution kit for the labeling of somatostatin analogue peptides, as well as for the localization of primary and/or metastatic lesions of NETs; and Annexin V-128, a SPECT radiopharmaceutical product candidate to detect early cell stress and apoptosis to assess programmed cell death in various pathological conditions, including rheumatoid arthritis. The company was founded in 2002 and is headquartered in Saint Genis Pouilly, France.

324 Employees
Last Reported Date: 01/29/15
Founded in 2002

advanced accelerator app-adr (AAAP) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: --
Group Chief Financial Officer
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: --
Head of Clinical Development
Total Annual Compensation: --
Chief Medical Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

advanced accelerator app-adr (AAAP) Key Developments

Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015

Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Advanced Accelerator Applications S.A. Announces Earnings Results for the First Nine Months of 2014

Advanced Accelerator Applications S.A. announced earnings results for the first nine months of 2014. For the nine months, sales of EUR 50,156,000 compared to EUR 38,919,000 a year ago. Operating income was EUR 2,199,000 compared to EUR 1,373,000 a year ago. Net income from continuing operations was EUR 1,135,000 compared to loss of EUR 2,038,000 a year ago. Adjusted EBITDA was EUR 9,668,000 compared to EUR 7,643.000 a year ago. Net operating cash-flow was EUR 9 million, an increase of 33% compared to the 6.7 million a year ago.

Advanced Accelerator Applications SA Announces Earnings Results for the Full Year Ended December 31, 2013

Advanced Accelerator Applications SA announced earnings results for the full year ended December 31, 2013. For the period, the company reported net loss for the year from continuing operations of EUR 9,861,000 compared with EUR 16,912,000 for the same period a year ago. EBITDA was EUR 10,638,000 compared with EUR 6,577,000 for the same period a year ago. Sales for the year increased by 31.77% to EUR 53.8 million compared with EUR 40.8 million for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AAAP:US $0.00 USD 0.00

AAAP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AAAP.
View Industry Companies

Industry Analysis


Industry Average

Valuation AAAP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED ACCELERATOR APP-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at